(Q78022202)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

title

The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference

1 reference

Shin DH

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

McCracken MS

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Bendel RE

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Pearlman R

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Juzych MS

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Hughes BA

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Schulz LL

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Kim C

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

Baek NH

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

publication date

1 February 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

page(s)

386-390

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect

10 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Ultrasound biomicroscopic study of ciliary body thickness after topical application of pharmacologic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Latanoprost and physostigmine have mostly additive ocular hypotensive effects in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Latanoprost for uncontrolled glaucoma in a compassionate case protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Latanoprost as a new horizon in the medical management of glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2899%2990053-2

7 January 2021

10.1016/S0161-6420(99)90053-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9951495%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference